Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells.
circulating tumor cells
detection
diagnosis
immunocytochemistry
non-invasive
prostate cancer
screening
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
11
01
2023
received:
09
07
2022
accepted:
16
01
2023
medline:
10
5
2023
pubmed:
1
2
2023
entrez:
31
1
2023
Statut:
ppublish
Résumé
The low specificity of serum PSA resulting in the inability to effectively differentiate prostate cancer from benign prostate conditions is a persistent clinical challenge. The low sensitivity of serum PSA results in false negatives and can miss high-grade prostate cancers. We describe a non-invasive test for detection of prostate cancer based on functional enrichment of prostate adenocarcinoma associated circulating tumor cells (PrAD-CTCs) from blood samples followed by their identification by immunostaining for pan-cytokeratins (PanCK), prostate specific membrane antigen (PSMA), alpha methyl-acyl coenzyme-A racemase (AMACR), epithelial cell adhesion molecule (EpCAM), and common leucocyte antigen (CD45). Analytical validation studies were performed to establish the performance characteristics of the test using VCaP prostate cancer cells spiked into healthy donor blood (HDB). The clinical performance characteristics of the test were evaluated in a case-control study with 160 known prostate cancer cases and 800 healthy males, followed by a prospective clinical study of 210 suspected cases of prostate cancer. Analytical validation established analyte stability as well as acceptable performance characteristics. The test showed 100% specificity and 100% sensitivity to differentiate prostate cancer cases from healthy individuals in the case control study and 91.2% sensitivity and 100% specificity to differentiate prostate cancers from benign prostate conditions in the prospective clinical study. The test accurately detects PrAD-CTCs with high sensitivity and specificity irrespective of stage, serum PSA or Gleason score, which translates into low risks of false negatives or overdiagnosis. The high accuracy of the test could offer advantages over PSA based prostate cancer detection.
Sections du résumé
BACKGROUND
The low specificity of serum PSA resulting in the inability to effectively differentiate prostate cancer from benign prostate conditions is a persistent clinical challenge. The low sensitivity of serum PSA results in false negatives and can miss high-grade prostate cancers. We describe a non-invasive test for detection of prostate cancer based on functional enrichment of prostate adenocarcinoma associated circulating tumor cells (PrAD-CTCs) from blood samples followed by their identification by immunostaining for pan-cytokeratins (PanCK), prostate specific membrane antigen (PSMA), alpha methyl-acyl coenzyme-A racemase (AMACR), epithelial cell adhesion molecule (EpCAM), and common leucocyte antigen (CD45).
METHODS
Analytical validation studies were performed to establish the performance characteristics of the test using VCaP prostate cancer cells spiked into healthy donor blood (HDB). The clinical performance characteristics of the test were evaluated in a case-control study with 160 known prostate cancer cases and 800 healthy males, followed by a prospective clinical study of 210 suspected cases of prostate cancer.
RESULTS
Analytical validation established analyte stability as well as acceptable performance characteristics. The test showed 100% specificity and 100% sensitivity to differentiate prostate cancer cases from healthy individuals in the case control study and 91.2% sensitivity and 100% specificity to differentiate prostate cancers from benign prostate conditions in the prospective clinical study.
CONCLUSIONS
The test accurately detects PrAD-CTCs with high sensitivity and specificity irrespective of stage, serum PSA or Gleason score, which translates into low risks of false negatives or overdiagnosis. The high accuracy of the test could offer advantages over PSA based prostate cancer detection.
Identifiants
pubmed: 36718027
doi: 10.1002/cam4.5649
pmc: PMC10166919
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9116-9127Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Eur Urol. 2014 Jun;65(6):1046-55
pubmed: 24439788
Eur Urol. 2015 Sep;68(3):464-70
pubmed: 25454615
Korean J Urol. 2014 Jul;55(7):436-45
pubmed: 25045441
Oncotarget. 2018 Nov 2;9(86):35705-35716
pubmed: 30479699
Sci Transl Med. 2010 Mar 31;2(25):25ra23
pubmed: 20424012
Eur J Cancer. 2011 Dec;47(18):2698-705
pubmed: 21788129
Ther Adv Urol. 2014 Apr;6(2):74-7
pubmed: 24688603
CA Cancer J Clin. 2010 Mar-Apr;60(2):70-98
pubmed: 20200110
Cytometry A. 2015 Feb;87(2):137-44
pubmed: 25515318
BMJ. 2009 Sep 24;339:b3537
pubmed: 19778969
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):607-614
pubmed: 32382078
Cancer Med. 2023 Apr;12(8):9116-9127
pubmed: 36718027
JAMA. 1998 May 20;279(19):1542-7
pubmed: 9605898
Ann Oncol. 2021 Sep;32(9):1167-1177
pubmed: 34176681
Cancer Chemother Pharmacol. 2021 Feb;87(2):197-205
pubmed: 33170321
J Clin Oncol. 2010 Jan 1;28(1):126-31
pubmed: 19917860
Curr Opin Biotechnol. 2016 Aug;40:9-15
pubmed: 26900985
Ann Oncol. 2007 Mar;18(3):518-21
pubmed: 17322541
N Engl J Med. 2004 May 27;350(22):2239-46
pubmed: 15163773
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Oncol. 2005 Jul;27(1):49-57
pubmed: 15942643
Am J Cancer Res. 2019 Jul 01;9(7):1309-1328
pubmed: 31392072
Cancer Lett. 2007 Aug 18;253(2):180-204
pubmed: 17314005
J Clin Pathol. 2011 May;64(5):415-20
pubmed: 21415054
Lancet. 1986 Jan 11;1(8472):60-3
pubmed: 2867314
Int J Cancer. 2020 Jun 15;146(12):3485-3494
pubmed: 31785151
Sci Rep. 2016 Dec 21;6:39736
pubmed: 28000772
BJU Int. 2013 May;111(5):753-60
pubmed: 23464824
Mol Oncol. 2021 Jun;15(6):1622-1646
pubmed: 33448107
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Urol Oncol. 2015 Sep;33(9):383.e9-16
pubmed: 26059076
Ann Oncol. 2020 Jun;31(6):745-759
pubmed: 33506766
Cancer. 2016 Jan 1;122(1):78-83
pubmed: 26371600
Cancer Cytopathol. 2021 Mar;129(3):226-238
pubmed: 32996712
N Engl J Med. 2004 May 27;350(22):2292-4
pubmed: 15163780
Br J Gen Pract. 2014 Dec;64(629):e783-7
pubmed: 25452543
Front Oncol. 2020 Apr 23;10:582
pubmed: 32391268
JCO Precis Oncol. 2019;3:
pubmed: 31528835
JAMA. 2014 Sep 10;312(10):995-6
pubmed: 25090603
Oncotarget. 2017 Jan 31;8(5):8801-8806
pubmed: 28187533
JAMA. 2018 May 8;319(18):1901-1913
pubmed: 29801017
PLoS One. 2014 Feb 14;9(2):e88967
pubmed: 24551200
JAMA. 2018 May 8;319(18):1914-1931
pubmed: 29801018
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Clin Cancer Res. 2009 Jan 15;15(2):677-83
pubmed: 19147774
N Engl J Med. 2022 Dec 8;387(23):2126-2137
pubmed: 36477032
Anticancer Res. 2015 Sep;35(9):4855-7
pubmed: 26254378